Peter Ho

2.8k total citations · 1 hit paper
48 papers, 2.0k citations indexed

About

Peter Ho is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Ho has authored 48 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 21 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Ho's work include HER2/EGFR in Cancer Research (9 papers), Chromatin Remodeling and Cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Peter Ho is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Chromatin Remodeling and Cancer (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Peter Ho collaborates with scholars based in United States, France and Netherlands. Peter Ho's co-authors include Wenle Xia, Lei-Hua Liu, Neil L. Spector, Malcolm A. Smith, Richard Pazdur, Steven Hirschfeld, Stephen J. Blakemore, Antoîne Italiano, Heike Keilhack and Scott Ribich and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Peter Ho

47 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Peter Ho	1.1k	780	354	302	205	48	2.0k
Yutaka Kawakami	777 0.7×	915 1.2×	409 1.2×	319 1.1×	90 0.4×	37	2.4k
Raushan T. Kurmasheva	1.3k 1.2×	814 1.0×	546 1.5×	236 0.8×	190 0.9×	120	2.3k
Yusri Elsayed	1.1k 1.0×	1.1k 1.4×	606 1.7×	235 0.8×	66 0.3×	51	2.4k
Oliver Bechter	767 0.7×	603 0.8×	214 0.6×	184 0.6×	85 0.4×	95	1.7k
Kathleen Cieply	940 0.9×	857 1.1×	737 2.1×	257 0.9×	348 1.7×	58	2.6k
Kanako C. Hatanaka	564 0.5×	613 0.8×	409 1.2×	191 0.6×	100 0.5×	143	2.0k
Dirk Behringer	630 0.6×	1.1k 1.4×	388 1.1×	145 0.5×	116 0.6×	69	2.2k
Francesco Galimi	1.1k 1.0×	1.2k 1.5×	444 1.3×	322 1.1×	83 0.4×	35	2.5k
Birgit M. Kräling	986 0.9×	739 0.9×	256 0.7×	130 0.4×	77 0.4×	12	1.9k
Romano Colombari	395 0.4×	1.0k 1.3×	612 1.7×	190 0.6×	85 0.4×	62	2.4k

Countries citing papers authored by Peter Ho

Since Specialization

Citations

This map shows the geographic impact of Peter Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ho more than expected).

Fields of papers citing papers by Peter Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ho. The network helps show where Peter Ho may publish in the future.

Co-authorship network of co-authors of Peter Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ho. A scholar is included among the top collaborators of Peter Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ho. Peter Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Italiano, Antoîne, Jean‐Charles Soria, Maud Toulmonde, et al.. (2018). Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology. 19(5). 649–659. 451 indexed citations breakdown →

Chan-Penebre, Elayne, Kelli Armstrong, Allison E. Drew, et al.. (2017). Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models. Molecular Cancer Therapeutics. 16(5). 850–860. 127 indexed citations

Ragguett, Renee‐Marie, et al.. (2017). Efficacy of levomilnacipran extended release in treating major depressive disorder. Expert Opinion on Pharmacotherapy. 18(18). 2017–2024. 2 indexed citations

Teshima, Christopher, Karen J. Goodman, Samina A. Turk, et al.. (2017). Increased Intestinal Permeability in Relatives of Patients With Crohn’s Disease Is Not Associated With Small Bowel Ulcerations. Clinical Gastroenterology and Hepatology. 15(9). 1413–1418.e1. 26 indexed citations

Chen, Vincent Chin‐Hung, Wei‐Che Chiu, Peter Ho, et al.. (2017). Prostate cancer and antidepressants: A nationwide population-based nested case-control study. Journal of Affective Disorders. 227. 834–839. 3 indexed citations

Schöffski, Patrick, Mark Agulnik, Silvia Stacchiotti, et al.. (2017). Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).. Journal of Clinical Oncology. 35(15_suppl). 11057–11057. 43 indexed citations

Rioux, Nathalie, Heike Keilhack, Blythe Thomson, et al.. (2015). Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). A135–A135. 2 indexed citations

Huang, Pearl S., Peter Ho, & Kang Zhang. (2011). A proposal: a comprehensive platform to characterize tumors in Chinese and improve success in cancer drug discovery and development. Chinese Journal of Cancer. 30(6). 363–367.

Holen, Kyle D., Chandra P. Belani, George Wilding, et al.. (2010). A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemotherapy and Pharmacology. 67(2). 447–454. 60 indexed citations

10.

Burris, Howard A., Suzanne F. Jones, Daphne Williams, et al.. (2010). A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Investigational New Drugs. 29(3). 467–472. 52 indexed citations

11.

Storniolo, Anna Maria, Mark D. Pegram, Beth Overmoyer, et al.. (2008). Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology. 26(20). 3317–3323. 89 indexed citations

12.

Chu, Quincy S., Garry Schwartz, Johann S. de Bono, et al.. (2007). Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 25(24). 3753–3758. 48 indexed citations

13.

Savage, S., Jaap Verweij, F. Eskens, et al.. (2006). A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. Journal of Clinical Oncology. 24(18_suppl). 3088–3088. 21 indexed citations

14.

Xia, Wenle, Lei-Hua Liu, Peter Ho, & Neil L. Spector. (2004). Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 23(3). 646–653. 197 indexed citations

15.

Murren, John R., Giuseppe Pizzorno, Walter J. McMurray, et al.. (2002). Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies. Cancer Biology & Therapy. 1(2). 130–135. 12 indexed citations

16.

Shields, Anthony F., Peter Ho, & John R. Grierson. (1999). The Role of Imaging in the Development of Oncologic Agents. The Journal of Clinical Pharmacology. 39(S1). 40S–44S. 6 indexed citations

17.

Smith, Malcolm A. & Peter Ho. (1996). Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Investigational New Drugs. 14(1). 11–22. 12 indexed citations

18.

Ishiguro, Kimiko, Peter Ho, & Alan C. Sartorelli. (1992). Characterization of the defect in a variant of HL-60 promyelocytic leukemia cells with reduced transferrin receptor expression. Somatic Cell and Molecular Genetics. 18(1). 45–63. 4 indexed citations

19.

Ho, Peter & Robert W. Tucker. (1989). Centriole ciliation and cell cycle variability during G₁ phase of BALB/c 3T3 Cells. Journal of Cellular Physiology. 139(2). 398–406. 24 indexed citations

20.

Husseinzadeh, Nader, et al.. (1988). Neuroendocrine (Merkel cell) carcinoma of the vulva. Gynecologic Oncology. 29(1). 105–112. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact